(Date:5/16/2008)...National HIV Vaccine Awareness Day, May,18, WASHI...x years into the,AIDS epidemic, someone is newly i...unday, May 18, HIV Vaccine Awareness Day, AIDS Act... Institute of Allergy and Infectious,Disease (NIAI...s everyone,to help end the AIDS epidemic by partic...
(Date:5/16/2008)...untsworth plc (LSE: HNT), "the Group",a leading i...nications,group headquartered in London, released ...Group,s performance in the first quarter 2008 (the...follows below., 15 May 2008, ...erim Management Statement, Record net ...
(Date:5/16/2008)... More in 2007, WASHINGTON, May 16 /PRNewswire-USN...cancer deaths, the National Cancer Institute (NCI)...in lung cancer research in 2007,according to upda...) today., The two other federal agencies with sig...isease Control and Prevention (CDC) and the,Depart...
(Date:5/16/2008)...Comprehensive Income increased 42% to $9.7 million... - 2007 Gross Margin of 76%, - Product Sales Back... million from $2.4 million as of December 31, 200...stCall/ -- Huiheng,Medical, Inc. ("Huiheng" or the...sed leader in the development, sales and support o...
Breaking Medicine News(10 mins):Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Lung Cancer Still Lowest in Federal Funding 2Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 2Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 3Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 4Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 5Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 6(Date:5/15/2008)...irstCall/ -- Sanofi-aventis,(EURONEXT: SAN and NYS...dmark ATHENA study showed Multaq(R) (dronedarone),... with atrial fibrillation or atrial flutter,decre...r death from any,cause by a statistically signific...endpoint. The ATHENA results will be presented at ...
(Date:5/15/2008)...tch, a publishing and,information services company... finds that investigative sites are required to le.... More than 75% of respondents to a recent,CenterW...n three or more,EDC systems. In addition, a majori...raining had improved., State of the Clinical Tria...
(Date:5/15/2008)...itions Blue Cross Blue Shield of Michigan to ... HealthLeaders-InterStudy, N...ers-InterStudy, the,leading provider of managed ca...y continues to stagnate in Michigan, Blue Cross Bl... all of its competitors to weather the,economic st...
(Date:5/15/2008)... Omega 3 fatty acids bound to,phospholipids deserv...alternative and may have beneficial effect on impu...udy reveals. While several studies have reported,b...nch researchers have,hypothesized that Vectomega(R...control., These research findings have led to the...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Veria Announces Acquisition of Massage Envy Ltd 19257 1Veria Announces Acquisition of Massage Envy Ltd 19257 2Veria Announces Acquisition of Massage Envy Ltd 19257 3China Sky One Medical Inc Changes Management Team 5371 1China Sky One Medical Inc Changes Management Team 5371 2China Sky One Medical Inc Changes Management Team 5371 3TOFUTTI Announces First Quarter Results 19251 1TOFUTTI Announces First Quarter Results 19251 2TOFUTTI Announces First Quarter Results 19251 3TOFUTTI Announces First Quarter Results 19251 4ImaRx Postpones Release of First Quarter 2008 Financial Results 5369 1...BUSINESS WIRE)--Apr 18, 2007 - Critical,Therapeuti...reclinical research demonstrating a role in chroni...y Group Box-1 protein (HMGB1), a,pro-inflammatory ...published in the May 2007 issue of Nature Immunolo...t of DNA complexes that,can stimulate immune cells...
...ociety for Biomolecular Sciences Conference, THE W...all/ --,Lexicon Genetics Incorporated announced th... therapeutic targets related to its,collaboration ...ar,Sciences 13th Annual Conference & Exhibitio...re made in a collaboration,between Lexicon and Gen...
Other Medicine Technology:Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5...uum Controller V-800 Efficiently controls vacuum...s V-500 on and off as needed to maintain preset va...ane vacuum pump designed to handle most vacuum app...with up to two rotary evaporators Laboratory vac...
...cooled secondary condenser to trap residual solven...acuum pump designed to handle most vacuum applicat...up to two rotary evaporators Laboratory vacuum s...entrators, gel dryers, and filtration apparatuses ...
...0 is a multi-tasking vacuum source and solvent rec...apor trap and a maintenance-free, oil-free vacuum ... wide-mouth glass condensation flask collects all ...posal. The UVS400 provides an ideal vacuum system ...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)
Medicine Products: